Literature DB >> 20346410

RCA-I-resistant CHO mutant cells have dysfunctional GnT I and expression of normal GnT I in these mutants enhances sialylation of recombinant erythropoietin.

John S Y Goh1, Peiqing Zhang, Kah Fai Chan, May May Lee, Sing Fee Lim, Zhiwei Song.   

Abstract

A large number of CHO glycosylation mutants were isolated by Ricinus communis agglutinin-I (RCA-I). Complementation tests revealed that all these mutant lines possessed a dysfunctional N-acetylglucosaminyltransferase I (GnT I) gene. Sequencing analyses on the GnT I cDNAs isolated from 16 mutant lines led to the identification of nine different single base pair mutations. Some mutations result in a premature stop codon whereas others cause a single amino acid substitution in the GnT I protein. Interestingly, expression of the normal GnT I cDNA in mutant cells resulted in enhanced sialylation of N-glycans. The sialylation of recombinant erythropoietin (EPO) produced in mutant cells that were co-transfected with GnT I was enhanced compared to that of EPO produced in wild type CHO cells. The enhanced sialylation of EPO produced by JW152 cells in the presence of GnT I over CHO-K1 cells is a result of increased sialylated glycan structures with higher antennary branching. These findings represent a new strategy that may be utilized by the biotechnology industry to produce highly sialylated therapeutic glycoproteins. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20346410     DOI: 10.1016/j.ymben.2010.03.002

Source DB:  PubMed          Journal:  Metab Eng        ISSN: 1096-7176            Impact factor:   9.783


  4 in total

Review 1.  Emerging technologies for making glycan-defined glycoproteins.

Authors:  Lai-Xi Wang; Joseph V Lomino
Journal:  ACS Chem Biol       Date:  2011-12-14       Impact factor: 5.100

2.  Producing recombinant therapeutic glycoproteins with enhanced sialylation using CHO-gmt4 glycosylation mutant cells.

Authors:  John S Y Goh; Yingwei Liu; Kah Fai Chan; Corrine Wan; Gavin Teo; Peiqing Zhang; Yuanxing Zhang; Zhiwei Song
Journal:  Bioengineered       Date:  2014-06-09       Impact factor: 3.269

3.  Glycoengineering of Mammalian Expression Systems on a Cellular Level.

Authors:  Kelley M Heffner; Qiong Wang; Deniz Baycin Hizal; Özge Can; Michael J Betenbaugh
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

4.  Metabolic engineering of Chinese hamster ovary cells: towards a bioengineered heparin.

Authors:  Jong Youn Baik; Leyla Gasimli; Bo Yang; Payel Datta; Fuming Zhang; Charles A Glass; Jeffrey D Esko; Robert J Linhardt; Susan T Sharfstein
Journal:  Metab Eng       Date:  2012-02-06       Impact factor: 9.783

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.